epclusa
gilead sciences ireland uc - sofosbuvir, velpatasvir - hepatitt c, kronisk - antivirale midler til systemisk bruk - epclusa is indicated for the treatment of chronic hepatitis c virus (hcv) infection in patients 3 years of age and older (see sections 4. 2, 4. 4 og 5.
harvoni
gilead sciences ireland uc - ledipasvir, sofosbuvir - hepatitt c, kronisk - antivirale midler til systemisk bruk - harvoni is indicated for the treatment of chronic hepatitis c (chc) in adult and paediatric patients aged 3 years and above (see sections 4. 2, 4. 4 og 5. for hepatitt c-virus (hcv) genotype-spesifikk aktivitet, se kapittel 4. 4 og 5.
orfiril long 500 mg
desitin arzneimittel gmbh - natriumvalproat - depotgranulat - 500 mg
orfiril long 1000 mg
desitin arzneimittel gmbh - natriumvalproat - depotgranulat - 1000 mg
orfiril long 150 mg
desitin arzneimittel gmbh - natriumvalproat - depotkapsel, hard - 150 mg
orfiril long 300 mg
desitin arzneimittel gmbh - natriumvalproat - depotkapsel, hard - 300 mg
orfiril 100 mg/ ml
desitin arzneimittel gmbh - natriumvalproat - injeksjonsvæske, oppløsning - 100 mg/ ml
orfiril 60 mg/ ml
desitin arzneimittel gmbh - natriumvalproat - mikstur, oppløsning - 60 mg/ ml
orfiril retard 300 mg
desitin arzneimittel gmbh - natriumvalproat - depottablett - 300 mg
vosevi
gilead sciences ireland uc - sofosbuvir, velpatasvir, voxilaprevi - hepatitt c, kronisk - antivirale midler til systemisk bruk - vosevi is indicated for the treatment of chronic hepatitis c virus (hcv) infection in patients aged 12 years and older and weighing at least 30 kg. (se kapittel 4. 2, 4. 4 og 5.